AMMF European Cholangiocarcinoma Conference May 2026
All AMMF’s sponsors which can be found below have supported AMMF’s 2026 Conference through a financial contribution only. They have not been involved in the content or any other aspect of the conference except as exhibitors and attendees.
Shaping the future: from early detection to improved survival
AMMF’s 2026 European 3-day Cholangiocarcinoma Conference will take place from 13–15 May at the Radisson Blu Hotel, conveniently located next to the London Stansted Airport and rail terminal.
AMMF’s annual conference is a unique and invaluable educational opportunity for all healthcare professionals and researchers with an interest in cholangiocarcinoma. As always, 2026 will include dedicated sessions for patients, carers, families and friends, too.
CCA-UK@AMMF2026
Each year, AMMF aims to deliver a world-leading event – and 2026 is no exception. For this conference, the multi-disciplinary specialist group Cholangiocarcinoma-UK* is partnering with AMMF to highlight the latest progress in the rapidly evolving treatment landscape for cholangiocarcinoma.
International Co-chairs
We are delighted to have international co-chairs Professor Brian Davidson (UK) and Dr Angela Lamarca (Spain) to lead a distinguished global faculty, as together they explore the 2026 theme, Shaping the future: from early detection to improved survival.
Join us for a truly collaborative experience, including:
- Presentations on progress in treatment advances
- International aspects of cholangiocarcinoma
- Updates from the research world of including AMMF-funded work
- Poster sessions showcasing new studies
- Personal perspectives from patient and carers
- Opportunities to build networks with those at the forefront of the CCA world
- And more …
Together we are driving progress and shaping the future. And together we will continue to push for better, faster, and fairer outcomes for everyone affected by CCA.
*Cholangiocarcinoma-UK (CCA-UK) is a multi-disciplinary group of clinicians, scientists and patient advocates whose purpose is to facilitate collaborative research, enhance service development and raise awareness of cholangiocarcinoma (CCA-UK is an affiliate of the British Association for the Study of the Liver (BASL))
All 2026 sessions are available to watch again
The AMMF 2026 European Cholangiocarcinoma Conference is over but all the presentations from each of the three days, 13, 14 and 15 May 2026, are available to watch again:
- For registered delegates: Watch on demand remains live for those registered delegates by using their original login details. Access in this way will remain available until early in 2026.
- For those who didn’t register for the conference: All the individual presentations have been uploaded to AMMF’s website and are available to view below
We very much hope that you will re-visit the event and join any sessions that you might have missed or would like to see again.
Please note: To abide by ABPI regulations, some parts of the conference programme and meeting platform are intended for Healthcare Professionals only.
| Topic | Presenter |
| Welcome to Day One and introduction to sessions | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Intro to AMMF and an overview of cholangiocarcinoma | Dr Helen Morement CEO, AMMF |
| Patient Perspective – “An Abundance of Caution” | Pamela |
| Targeted therapies / Immunotherapies – what are they, how are they different, and clinical trials | Professor John Bridgewater University College London Hospitals, NHS Foundation Trust, Cancer Institute |
| Liquid Biopsy | Dr Magda Meissner Velindre Cancer Centre and Cardiff University |
| Surgery for CCA | Mr Hassan Malik Liverpool University Hospitals NHS Foundation Trust |
| Question Time – 15:15 – 15:25 | Panel Presenters Dr Helen Morement – CEO and Founder Professor John Bridgewater – Consultant Medical Oncologist Dr Magda Meissner – Clinical Senior Lecturer, Medical Oncology Consultant, Clinical Liquid Biopsy Lead Mr Hassan Malik – Consultant General and Hepatobiliary Surgeon |
| Health-Related Quality of Life of Patients with Cholangiocarcinoma: A Qualitative Study from the EORTC QoL Rare Cancer study | Catarina S. Padilla Department of Medical oncology, The Netherlands Cancer Institute, Amsterdam & Department of Public Health and Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands |
| Transplantation for CCA | Professor Douglas Thorburn University College London Royal Free London, NHS Foundation Trust |
| Research and the hidden role of pathology in the CCA patient’s clinical journey | Professor Tim Kendall University of Edinburgh |
| Question time – 16:25 – 16:35 | Panel Presenters Catarina S. Padilla – PhD Candidate Professor Douglas Thorburn – Professor of Hepatology, Clinical Director for Liver Services Professor Tim Kendall – Personal Chair of Liver Pathology |
| Closing Comments – End of Day One | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Topic | Presenter |
| Co-Chairs Welcome | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| AMMF Updates | Dr Helen Morement CEO, AMMF |
| National Cancer Plan TBC | Shane Cohen-Murray Department of Health and Social Care |
| Question Time 9:05 – 9:15 | Panel Presenters Dr Helen Morement – CEO and Founder Shane Cohen-Murray – Head of Cancer Strategy, Cancer Policy and Performance Team |
| Session co-chairs welcome | Dr Valerie Crolley Royal Free London, NHS Foundation Trust Professor Shahid Khan Imperial College Healthcare, NHS Trust |
| CCA Epidemiology – new data | Professor Shahid Khan Imperial College Healthcare, NHS Trust Mr Arjun Narendran Imperial College London |
| Molecular profiling across the UK | Dr Matt Evans University Hospitals Birmingham NHS Foundation Trust and Central & South Genomic Medicine Service |
| Targeted therapies, immunotherapies, trial updates (ABC-10, SAFIR IMPACT) | Professor John Bridgewater University College London Hospitals, NHS Foundation Trust, Cancer Institute |
| Radiotherapy in BTC | Professor Maria Hawkins University College London |
| Question Time 10:45 – 11:00 | Panel Presenters Professor Shahid Khan – Professor of Practice (Hepatology) Mr Arjun Narendran – Imperial College London Dr Matt Evans – Consultant Cellular Pathologist Professor John Bridgewater – Consultant Medical Oncologist Professor Maria Hawkins – Professor of Radiation Oncology |
| Patient Perspective | Benjamin Carey |
| The Aspirin Study | Professor Shahid Khan Imperial College Healthcare, NHS Trust |
| BSG Guidelines on the diagnosis and management of GBC | Professor Dhanny Gomez Nottingham University Hospitals, NHS Trust |
| Optimising the surgical management of CCA | Professor John Primrose University Hospital Southampton, NHS Foundation Trust |
| Liver Transplantation in CCA | Professor Douglas Thorburn University College London Royal Free London, NHS Foundation Trust |
| Question Time 12:50-13:10 | Panel Presenters Professor Shahid Khan – Professor of Practice (Hepatology) Professor Dhanny Gomez – Consultant Hepato-Pancreato-Biliary (HPB) Surgeon Professor John Primrose – Professor of Surgery within Medicine Professor Douglas Thorburn – Professor of Hepatology, Clinical Director for Liver Services |
| Co-chair introduction to afternoon and first session | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Adherence to best practice guidelines for the management of intrahepatic CCA: results from the UK nationwide CAPBIL study | Ms Jane McClements Belfast City Hospital, Belfast Health and Social Care Trust |
| Spotlight on CCA in Wales | Ms Trish Duncan University Hospital of Wales |
| Update on SIRT | Professor Julien Edeline Centre Eugene Marquis, Rennes University, France |
| Question Time 15:05 – 15:15 | Panel Presenters Ms Jane McClements – Consultant Hepatobiliary Surgeon Ms Trish Duncan – Consultant Hepatobiliary Surgeon/HPB Clinical Lead Professor Julien Edeline – Medical Oncologist |
| Patient Perspective -“It’s Difficult to sum up what I’ve gone through in a title” | Gareth Honeybone |
| Co-chairs Introduction to international sessions | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Screening and surgery for CCA: The Thai Experience | Professor John Primrose University Hospital Southampton, NHS Foundation Trust |
| Published Biomarker Work | Professor Watcharin Loilome Khon Kaen University, Thailand |
| CCA in Spain | Dr Angela Lamarca Fundación Jiménez Díaz University Hospital (Madrid, Spain) |
| Update on the work of Precision BTC Network | Professor Rocío Macías University of Salamanca, IBSAL, CIBEREHD, Spain |
| Question Time 17:10 – 17:20 | Panel Presenters Professor John Primrose – Professor of Surgery within Medicine Assoc.Prof.Dr Watcharin Loilome – Cholangiocarcinoma Research Institute, Khon Kaen University (CARI), Director Dr Angela Lamarca – Consultant (FEA) in Medical Oncology Professor Rocío Macías – University Professor |
| Closing Comments – End of Day Two | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Topic | Presenter |
| Welcome to Day 3 | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Patient Perspective | Charlie Shrager |
| Introduction to session | Professor Luke Boulter Institute of Genetics and Cancer, University of Edinburgh Professor Sheela Jayaraman University of Nottingham |
| Take a deep breath: How a breath test could revolutionise the early detection of liver cancer. | Dr Georgios Karagiannidis Imperial College, London |
| Histotripsy Non-invasive, Non-ionisation, Non-thermal Liver Surgery | Dr Teik Choon See Cambridge University Hospitals, NHS Foundation Trust |
| Next generation liquid biopsy biomarkers for CCA | Professor Jesús Bañales Biogipuzkoa Institute (Spain) |
| ATTAINMENT Study | Jemma Proudfoot-Jones Liverpool Experimental Cancer Medicine Centre, University of Liverpool, and the Clatterbridge Cancer Centre |
| Question Time 10:40 – 10:55 | Panel Presenters Dr Georgios Karagiannidis – Clinical Research Fellow Dr Teik Choon See – Consultant Interventional Radiologist Professor Jesús Bañales – Professor of Molecular Biology and Head of the Liver Diseases Group, Professor of Sciences Jemma Proudfoot-Jones – University of Liverpool and the Clatterbridge Cancer Centre |
| AMMF and AstraZeneca in Conversation: Collaborating for Progress in Cholangiocarcinoma | Emma Purdy AstraZeneca UK Dr Helen Morement AMMF – The Cholangiocarcinoma Charity |
| Introduction to Session | Professor Luke Boulter Institute of Genetics and Cancer, University of Edinburgh Professor Sheela Jayaraman University of Nottingham |
| Normal cholangiocyte containment of cholangiocarcinoma through metabolic and transcriptomic regulation | Professor Shijie Cai University of Oxford |
| The role of IDH mutation in liver cell plasticity and intrahepatic cholangiocarcinoma | Ms Rachel Guest University of Edinburgh |
| Interrogating tumour mediated immunosuppression in peri-hilar cholangiocarcinoma | Dr Laura Randle University of Liverpool |
| Question Time 12:30 – 12:45 | Panel Presenters Professor Shijie Cai – Associate Professor of Experimental Cancer Medicine Ms Rachel Guest – Honorary Consultant Hepatopancreatobiliary Surgeon and Senior Clerical Lecturer Dr Laura Randle – Senior Lecturer, Deputy HoD Pharmacology and Therapeutics |
| AI-CCA: Artificial Intelligence as a Biomarker for Intrahepatic Cholangiocarcinoma | Arezoo Ghodsifard Hôpital Henri Mondor, France |
| Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology | Professor Joshua Edel Imperial College London |
| Question Time 14:15 – 14:25 | Panel Presenters Arezoo Ghodsifard – PhD Student Professor Joshua Edel – Professor of Biosensing & Analytical Sciences |
| Introduction to Fast Science Session | Professor Tim Kendall The University of Edinburgh Professor Kevin Gaston The University of Nottingham |
| Defining Metabolic Zonation as a Determinant of Hepatocyte Plasticity | Caitlin McCaffrey Institute of Genetics and Cancer, University of Edinburgh |
| Human Precision-Cut Tumour Slices (hPCTS) and Immune Co-Culture Systems to Assess and Enhance Immunotherapy Response in Cholangiocarcinoma | Maria-Danae Jessel Department of Pharmacology and Therapeutics, The University of Liverpool” |
| Immune Profiling of Cholangiocarcinoma and Evaluation of Human Precision-Cut Tumour Slices as an Ex Vivo Model | Owen McGreevy Institute of System, Molecular and Integrative Biology, Pharmacology and Therapeutics, The University of Liverpool |
| The Centrosome-Ciliary genes as a therapeutic target in bile duct cancer | Dr Emanuele Manco Department of Translational Medical Science, University of Naples Federico II, Italy |
| Question Time 15:10 – 15:25 | Panel Presenters Maria-Danae Jessel – The University of Liverpool Owen McGreevy – The University of Liverpool Dr Emanuele Manco – University of Napels Federico II, Italy |
| ‘Fast Science’ and Best Poster award presentations | Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
| Conference highlights and closing remarks | Dr Helen Morement CEO, AMMF Professor Brian R. Davidson Royal Free London, NHS Foundation Trust University College London Dr Angela Lamarca Fundación Jiménez Diaz University Hospital |
Conference Programme
Discover what’s in store at the AMMF 2026 European Cholangiocarcinoma Conference. Hear from leading experts and explore the latest advances in research. Our programme is designed to provide an overview of current developments in cholangiocarcinoma.
*Programme details are subject to change
AMMF Conference Sponsor 2026
All AMMF’s sponsors have supported AMMF’s 2026 Conference through a financial contribution only. They have not been involved in the content nor in any other aspect of the conference
BASL Endorsed
AMMF’s 2026 European Cholangiocarcinoma Conference is a BASL* endorsed event.
CPD Accreditation
AMMF’s 2026 European Cholangiocarcinoma Conference is a CPD accredited event. Attendance to the full three day conference is worth 19.45 hours CPD.
CPD eligibility
Attendance at AMMF’s 3-day CCA Conference is worth a total 19.45 hours CPD. It is the responsibility of each delegate to claim only for the hours they have attended.
Abstracts Closed
The call for abstracts is now closed. For further details, please click here.
Previous Conferences
For details of previous AMMF European Cholangiocarcinoma Conferences, including recordings of the presentations, please go to: https://ammf.org.uk/ammf-conference/
